Cannabis Law Report

AUGUST 12, 2021

Drug Enforcement Administration’s (DEA) refusal to accommodate state and federal right to try laws. US DEA , No. US DEA , No. RTT laws permit certain patients who have been diagnosed with life-threatening diseases or conditions access to investigational medications not yet approved for general use by the U.S.

DEA 105

DEA Medicine Food Patients 105

Cannabis Law Report

MARCH 10, 2021

Marijuana Moment reports A Seattle doctor hoping to expand access to psilocybin mushrooms for terminally ill cancer patients is taking… Read More. The post USA: Dr Suing DEA Over Right To Give Patients Psilocybin Treatment first appeared on Cannabis Law Report.

DEA 85

DEA Treatment Patients Access 85

Cannabis Law Report

AUGUST 26, 2019

DEA Announces Steps Necessary to Improve Access to Marijuana Research. The DEA is providing notice of pending applications from entities applying to be registered to manufacture marijuana for researchers. percent delta-9 THC threshold, is not a controlled substance, and a DEA registration is not required to grow or research it.

DEA 59

DEA Access Marijuana Programs 59

NORML

DECEMBER 9, 2020

The reality that most high-schoolers have easier access to cannabis than do our nation’s top scientists is the height of absurdity and an indictment of the current system.”. “These common-sense regulatory changes are necessary and long overdue.

Access 246

Access Marijuana Clinical Trials Cannabis 246

SpeedWeed

MARCH 11, 2021

“The case is about seeking to ensure that patients with serious, life-threatening illness are able to realize the promise of state and federal Right to Try laws and access psilocybin for therapeutic purposes.”. At that point, the team decided to sue the DEA to change its decision. “I We don’t have much of an explanation at all.”

DEA 52

DEA Patients Access Advocacy 52

Cannabis Law Report

DECEMBER 7, 2021

On November 16, 2021, the Drug Enforcement Agency (DEA) issued an advance notice of proposed rulemaking , exploring whether or not to create new federal regulations governing the practice of telepharmacy. The DEA’s notice provides the industry with an opportunity to provide insight and feedback that may help shape the new regulations.

DEA 52

DEA Patients Therapy Access 52

SpeedWeed

MAY 24, 2021

The Drug Enforcement Administration made a milestone announcement earlier this month with the news that the DEA will begin granting marijuana cultivation licenses to various third-party applicants, significantly expanding medical and scientific cannabis research in the United States.

DEA 52

DEA Cultivation Research and Development Marijuana 52

MJ Business Attorneys

JUNE 29, 2018

Moreover, the ball is in the Drug Enforcement Agency’s (DEA) court. The FDA can make recommendations to the DEA about substances subjected to scheduling under the CSA, but the DEA is the entity with the power to reschedule CBD. In the recent case Hemp Industries Associations v.

DEA 113

DEA CBD Pharmaceutical Research and Development 113

The Cannigma

JUNE 14, 2021

All that is about to change, thanks to a change at the DEA , which cultivators and industry experts say will be monumental for cannabis research, medical marijuana patients, and potentially the broader legal status of the plant itself. “We BRC) told The Cannigma this week. Junk’ cannabis ‘ill-suited for clinical trials’. Shutterstock).

DEA 133

DEA Research and Development Clinical Trials Pharmaceutical 133

Americans for Safe Access

JUNE 2, 2020

On March 23, DEA published a proposed rulemaking —“Controls to Enhance the Cultivation of Marihuana for Research in the United States”—in the Federal Register (85 FR 16292), involving who can grow cannabis in bulk for research purposes.

Clinical Trials 230

Clinical Trials DEA History Programs 230

Cannabis Law Report

MARCH 24, 2020

The DEA says the proposed rule will see additional registered growers and more diverse variety of marijuana strains available for research. Currently, the DEA has 37 pending applications to grow marijuana for research. DEA Publishes Notice of Proposed Rulemaking On Marijuana Research.

DEA 80

DEA Marijuana Extraction Strains 80

Americans for Safe Access

APRIL 2, 2019

The Americans for Safe Access 2019 Unity Conference, themed The Price of Being a Medical Cannabis Patient, featured over a hundred patients from all over America visiting their representatives in Congress and the Senate to promote the Medical Cannabis Control Act of 2019.

Access 100

Access DEA Policy Patients 100

Veriheal

JANUARY 16, 2024

This occasion marks the first time that a federal agency has recommended rescheduling cannabis, and this could be the push the Drug Enforcement Administration (DEA) needs to finally make it happen. It may also result in federal legalization and easier access in states that have yet to legalize medicinal or recreational marijuana.

DEA 119

DEA Medicine Cannabis Legalization 119

WeedAdvisor

AUGUST 28, 2019

Despite a 90-day deadline for review, the DEA ignored this cut-off and simply sat on the applications for three years. This likely would have been longer, but the DEA had not anticipated a legal threat to force some action. Given the DEA’s stonewalling, forcing their hand is a notable achievement. Dozens of Applications”. .

DEA 61

DEA Marijuana History THC 61

Americans for Safe Access

MAY 25, 2021

You will also find out how to access the recorded panels from Unity 2021 to catch anything you missed. Information on research steps from NIDA and DEA, House progress on SAFE Banking and other key bills, Developments in Alabama and Mississippi a call to action for veterans and a profile of ASA's 2021 Researcher of the Year, Philippe Lucas.

Research and Development 148

Research and Development DEA Banking Access 148

Veriheal

DECEMBER 30, 2020

If you answered yes to these two questions, then the DEA might have the job for you. The DEA is seeking a contractor that has the ability to destroy illegal drugs without leaving detectable levels behind. .” The DEA Says That This isn’t a Job Announcement . What about the bird’s man? Requirements of the Role.

DEA 52

DEA Pharmaceutical Packaging Business 52

Veriheal

DECEMBER 19, 2023

A new delta-8 study has revealed that people in states without access to legal cannabis products are far more likely to seek out and consume delta-8 and delta-9 variants, whether it be flower, edibles, or tinctures. To learn more about your access to medical cannabis or legal products, talk to one of our doctors today.

Legalization 113

Legalization Edibles DEA Access 113

WeedAdvisor

JUNE 1, 2019

The court, citing concerns over marijuana’s Schedule I status and its impact on medical users who need it most, essentially issued an ultimatum to the DEA. Like a child who does not want to clean his or her room, the DEA simply refuses to take any major action, despite the whirlwind of reforms surrounding them on a daily basis.

DEA 55

DEA Marijuana History Cannabis 55

NORML

MARCH 1, 2019

” Last year, however, former DEA director Robert Patterson testified to Congress that the agency believed that approving additional applicants would likely violate international anti-drug treaties. Patterson said that DEA could not move forward granting any new applications until the Justice Department clarified the issue.

DEA 168

DEA Research and Development Clinical Trials Marijuana 168

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. “Patients will benefit from cGMP-quality therapies in an accessible and efficient format.”. . Most recently the FDA awarded MMJ International Holdings ? .

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

MARCH 30, 2022

NORML has long advocated for amending federal regulations so that federally-licensed scientists can directly access and assess the wide variety of cannabis products readily available in medical-use and adult-use state markets. The full text of S. 253 is online here. Additional information is available from NORML here.

Legislation 95

Legislation Clinical Trials DEA Access 95

Marijuana Lawyer Blog

JANUARY 12, 2019

Defendants are acting-Attorney General Matthew Whitaker, the acting director of the DEA and the federal government. Additional Resources: Appeal Hearing in Cannabis Lawsuit Against the DEA , Dec. Although the lower federal court (U.S. Call us at 714-937-2050. 13, 2018, By Megan L’Heureux , Cannabis Science Tech.

DEA 40

DEA Patients Epilepsy Medicine 40

Cannabis Law Report

MAY 10, 2022

Activists staged a demonstration outside of the Drug Enforcement Administration (DEA) headquarters in Virginia on Monday, demanding that the agency allow terminally ill patients to access psilocybin therapy. Marijuana Moment reports. DeaOutoftheway @RTTpsilocybin pic.twitter.com/1NJWt2cJWn. aeidinger) May 9, 2022.

DEA 52

DEA Therapy Access Patients 52

Cannabis Law Report

JUNE 16, 2022

Lack of access to banking services and capital, high barriers to entry into legal cannabis markets, and exorbitant tax rates at all levels of government are clearly hampering the ability of licensed cannabis businesses to compete with the unregulated market.

DEA 52

DEA Marijuana Programs Data 52

Veriheal

MARCH 6, 2024

Department of Health and Human Services (HHS) recommended that the Drug Enforcement Agency (DEA) reshedule cannabis as a Schedule III substance in August of 2023. As it currently stands, the Controlled Substance Act makes it incredibly difficult for the DEA and outside research groups to grow cannabis products for the purpose of research.

Research and Development 62

Research and Development DEA Chronic Pain Business 62

Cannabis Law Report

NOVEMBER 2, 2022

Drug Enforcement Administration and the legal team representing terminally ill patients petitioning for access to psilocybin-assisted therapy. In late September, the DEA denied an official petition requesting that the agency look into rescheduling psilocybin from Schedule I to Schedule II.

Microdosing 52

Microdosing DEA Therapy Access 52

Cannabis Law Report

JULY 29, 2020

The case appears to be one of the first clashes between the California cannabis agency and federal agents over access to license-related records. California pushed … Read More.

DEA 59

DEA Access Cannabis 59

Cannabis Law Report

DECEMBER 15, 2019

Domestic Hemp Production Program must be registered with the Drug Enforcement Administration (DEA) to handle controlled substances. The directory below summarizes hemp testing laboratories who are registered with the DEA. Click on image to access the directory. This directory is provided for informational purposes only.

Hemp 59

Hemp DEA Concentrates Programs 59

SpeedWeed

APRIL 2, 2021

Hawaii House Approves Proposal For Cannabis Exemption From DEA. Hawaii lawmakers approved Wednesday a proposal that seeks an exemption from Drug Enforcement Administration (DEA) regulations, asking that the state is allowed to manage its medical cannabis program without federal involvement, reported Marijuana Moment.

DEA 52

DEA Programs Access Patients 52

Cannabis Law Report

JULY 7, 2021

Pennington, who focuses on federal appeals and regulatory issues, is co-counsel on several high-profile cases against the DEA regarding cannabis research, hemp, and psychedelics. Circuit), a pending petition for review of DEA’s August 2020 Interim Final Rule purportedly implementing the 2018 Farm Bill’s amendments to the CSA.

DEA 111

DEA Hemp Cultivation Advocacy 111

Canna Law Blog

AUGUST 16, 2022

As a refresher, the Drug Enforcement Administration (DEA) conducts the licensing process that enables researchers to gain access to cannabis product. The DEA still views cannabis as a controlled substance with “no known medical uses.” See: Not All Cannabis Reform is a Good Thing.).

DEA 66

DEA Access Cannabinoids Cannabis 66

Cannabis Law Report

FEBRUARY 10, 2022

Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). By Allison Campbell.

DEA 52

DEA Clinical Trials Policy Research and Development 52

Cannabis Law Report

MARCH 7, 2020

In its performance budget submission to Congress for fiscal year 2021, DEA gave an overview of its enforcement efforts and made predictions about future trends. In its performance budget submission to Congress for fiscal year 2021, DEA gave an overview of its enforcement efforts and made predictions about future trends.

DEA 64

DEA THC Retail Access 64

Cannabis Law Report

OCTOBER 4, 2021

Accordingly, it cannot be prescribed by a physician and it is not legally accessible to those who might benefit from it as a therapeutic treatment. Access Pursuant to the Oregon Psilocybin Services Act. Access to Psilocybin Therapy Pursuant to Right to Try Laws. Source: [link].

Therapy 52

Therapy Patients Law Clinical Trials 52

Veriheal

SEPTEMBER 13, 2022

It also may be more convenient to grow cannabis at home if a consumer lives in a rural area or in a state that only has a limited number of accessible dispensaries. Consumers are getting fed up with only having access to the same limited set of genetics in the dispensary. Homegrown cannabis gives all the power to the consumer.

Cultivation 109

Cultivation Data DEA Dispensary 109

Americans for Safe Access

JUNE 6, 2019

Drug Enforcement Administration (DEA) to reschedule cannabis, before filing suit. The plaintiffs appealed his decision.

DEA 204

DEA Patients Cannabis 204

NORML

JANUARY 15, 2020

Eleven states regulate the adult use of marijuana and 33 states provide for medical cannabis access. Strait, Senior Policy Advisor, Diversion Control Division, Drug Enforcement Administration (DEA). He continued: “The fact of the matter is that legalization and regulation work. Witnesses at today’s hearing were: Matthew J.

Policy 194

Policy DEA Legislation Data 194